Vascular Solutions downgraded to Hold from Buy at Benchmark Co. Benchmark Co. downgraded Vascular Solutions citing valuation following the company's Q4 results. The firm keeps a $17 price target for shares.
Vascular Solutions raises 2014 revenue outlook to $125M-$126M Previous outlook $123M-$125M. Consensus $123.75M. Due to the non-cash tax adjustment incurred in Q3 and increased legal expenses, Vascular Solutions is revising its GAAP earnings guidance for 2014 to a range of 65c-67c. Consensus 76c.